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ABSTRACT
Objective: To pilot a process for identifying and switching high-risk warfarin patients to direct oral anticoagulants (DOACs) in
nonvalvular atrial fibrillation (AF) or venous thromboembolism (VTE).
Methods: A pharmacy resident identified high-risk warfarin patients using three criteria. The resident reviewed medical charts,
communicated recommendations to the primary care physician (PCP), and scheduled patients for appointments to switch to
DOACs. Patients were followed every 1 to 3 months after initiating DOACs. The primary outcome of the study was the percentage
of high-risk warfarin patients before and after process implementation. Secondary outcomes at 6 months included bleeding or
thrombotic events, patient-reported side effects, recommendation acceptance rates, adherence rates, clinic time in therapeutic
range (TTR), and patient satisfaction.
Results: Out of 76 patients evaluated, 22.4% were identified as high-risk using the pre-specified criteria. After program
implementation, this percentage was reduced to 9.2%. No significant adverse events occurred by 3-month follow-up, and 100%
of recommendations were accepted by physicians. Adherence rates and clinic TTR also improved after implementation (87.5% to
94% and 60.9% to 81.1%, respectively). Overall, patients reported satisfaction with switching from warfarin to DOAC.
Conclusions: A pilot process was successful in reducing the percentage of high-risk warfarin patients by switching to DOAC
therapy.
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1. INTRODUCTION
Atrial fibrillation (AF) is a common cardiac arrhythmia en-
countered in clinical practice. AF is associated with a high
rate of cardiovascular and cerebrovascular morbidity and
mortality resulting in significant healthcare resource utiliza-
tion and public health burden.[1] The estimated US preva-
lence of AF of 5.1 million is predicted to increase to 9.3
million by 2030.[2] Venous thromboembolism (VTE) is the
third most common cardiovascular illness after acute coro-
nary syndrome and stroke. The precise number of people
affected by VTE is unknown, but the overall annual inci-
dence of VTE in the United States is estimated to be between
1 and 2 per 1,000.[3] Given the high prevalence of these dis-
ease states, there is strong need to optimize anticoagulation
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therapy because it is the mainstay for the prevention of stroke
in the setting of AF and for the treatment and prevention of
VTE.
Discovered in the 1920s and approved for clinical use in the
1950s, anticoagulation with warfarin has been the standard
of care for decades. However, optimal anticoagulation with
warfarin has remained challenging because of multiple drug-
drug and food-drug interactions, genetic variability, and nar-
row therapeutic index. Warfarin requires regular monitoring
and dose adjustments to maintain a therapeutic international
normalized ratio (INR).[4]
In 2010 the Food and Drug Administration approved dabiga-
tran, a direct oral anticoagulant (DOAC) for the prevention
of stroke or systemic embolism in the setting of non-valvular
atrial fibrillation (NVAF) which excludes those with me-
chanical prosthetic heart valves or moderate to severe mitral
stenosis. Subsequently, other DOACs have been approved
including rivaroxaban, apixaban, and edoxaban. DOACs
provide comparable or better efficacy and safety, predictable
pharmacokinetics, less drug-drug and drug-food interactions,
and no routine therapeutic laboratory monitoring.[5] National
guidelines now include DOACs as recommended treatment
options along with warfarin.[6, 7] Structured follow-up and
monitoring is recommended for patients and can be taken on
by pharmacists in various settings.[8]
Patients on long-term warfarin may be optimally managed
and maintained on warfarin; however, options are limited
for patients experiencing challenges yet requiring long-term
anticoagulation therapy.[9] Some options include increasing
the INR target for patients experiencing a thrombotic event
while being within the target INR range or switching to an-
other agent such as unfractionated heparin, low molecular
weight heparin, aspirin, or a DOAC. To date, there are no
identified published reports of a systematic approach to select
appropriate patients on warfarin to switch to a DOAC. Time
in therapeutic range (TTR) is often used as a quality marker
for anticoagulation management for patients maintained on
warfarin but its utility may be limited in patients such as new-
starts or those experiencing medication changes.[10] The
SAMe-TT2R2 is a scoring tool developed for AF patients
that may help with selection between warfarin and DOAC
therapy.[11] The purpose of this study was to pilot a process
for identifying and switching high-risk warfarin patients to
DOACs in NVAF or VTE.
2. METHODS
Cone Health Internal Medicine Center is a primary care clinic
within Moses H. Cone Memorial Hospital that provides care
for adult patients regardless of financial status. It is part
of Cone Health Medical Group and is the teaching site for
the Internal Medicine Residency Program. Clinic staff con-
sists of 12 attending and 22 resident physicians, a social
worker, financial counselor, dietician, nurses, and clinical
pharmacists (approximately 0.6 full time equivalent [FTE]
split faculty positions). Payor mix consists of approximately
45% Medicare, 15% Medicaid, 15% commercial, and 10%
self-pay. Charity care comprises about 20% of the popula-
tion. The pharmacist-run Anticoagulation Clinic cares for
approximately 130 patients and utilizes Dose Response R© to
monitor INR and TTR via the Rosendaal method.
This was a single-center quality improvement study approved
by Cone Health Institutional Review Board. A pharmacy
resident used three criteria to categorize warfarin patients
as high-risk. First, patients with a suboptimal history of
therapeutic INR laboratory values were defined as having a
one-year TTR < 60%. The second criterion required a poor
history of clinic attendance defined as less than 75% com-
pleted appointments within one year. The third criterion re-
quired a SAMe-TT2R2 score greater than 2, indicating a high
probability of subtherapeutic warfarin control.[10] Patients
who met all three criteria were evaluated by the pharmacy
resident for switch to a DOAC.
Eligible patients for the study were at least 18 years of age on
warfarin with an active profile within the DoseResponse R©
system. Patients were excluded if they had a contraindica-
tion to a DOAC (i.e. mechanical prosthetic valve) or were
already switched to a DOAC prior to patient encounter. The
full description of inclusion and exclusion criteria is illus-
trated in Figure 1. The pharmacy resident reviewed medical
charts, communicated recommendations to the primary care
physician (PCP), and scheduled patients for appointments to
switch to DOACs. The pharmacy resident collaborated with
nurses, social worker, financial counselor, or clerical staff
as appropriate to coordinate care for each patient. During
the initial appointment, INR and other appropriate laboratory
parameters (e.g. renal or hepatic function) were obtained.
Lastly, patients were provided education regarding their med-
ical condition and the appropriate use of the DOAC. Phar-
macy resident follow up appointments occurred 1 month and
3 months after DOAC initiation, and a phone call occurred
at 6 months including a patient satisfaction survey.[8] Pa-
tients and pharmacies were also contacted monthly to review
adherence.
The primary outcome of the study was percentage of high-
risk warfarin patients. Secondary outcomes at 6 months
following DOAC initiation included major bleeding events,
as defined by the International Society of Thrombosis and
Haemostasis (fatal bleeding, and/or symptomatic bleeding
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in a critical organ or area, and/or bleeding causing a fall in
hemoglobin level of ≥ 2 g/dl or 1.24 mmol/L leading to
≥ 2 units of transfused whole blood or red cells),[12] new
or recurrent thrombotic events, any patient-reported side ef-
fects, and patient satisfaction. Additional analyses included
physician acceptance of recommendations, total number of
successful patients transitioned during the study period, and
overall clinic TTR pre-post intervention. Medication adher-
ence was evaluated by calculating the medication proportion
of days covered (PDC) after contacting pharmacies for refill
histories.
Figure 1. Inclusion and exclusion criteria
Figure 2. Enrollmen
3. RESULTS
A total of 106 clinic patients were identified for screening
from the Dose Response R© system (see Figure 1). Thirty
patients (28.3%) were excluded for contraindications to a
DOAC (10), currently receiving a DOAC (6), discontinued
anticoagulation therapy (8), or being lost to clinic follow-
up (6). Seventy-six patients were evaluated of which 17
(22.4%) were identified as high-risk due to meeting all three
pre-specified criteria (see Figure 2).
The mean age of the high-risk population was 57.5 years
with 2 patients being of Caucasian descent (see Table 1). The
most common indication for anticoagulation therapy was
VTE, which was consistent with the overall clinic popula-
tion. The majority of the high-risk patients had concomitant
hypertension and tobacco use within the past 2 years, 76.5%
and 70.6% respectively. In this high-risk group, the mean
TTR for was low at 34.6%. Likewise, clinic appointment
attendance was poor at 56.7%. The mean SAMe-TT2R2 was
4.8 (range 3-7).
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Table 1. Baseline characteristics
 
 
Patient Characteristic Overall Warfarin Population (N = 76)  High-risk Warfarin Patients (N = 17) 
Age, years 60.1 57.5 
 Race – white, no. (%) 24 (31.6) 2 (11.8) 
 Sex – male, , no. (%) 38 (50.0) 6 (35.3) 
 Atrial fibrillation, no. (%) 24 (31.6) 6 (35.3) 
 Venous thromboembolism, no. (%) 52 (68.4) 11 (64.7) 
Comorbidities 
 CHF, no. (%) 11 (14.5) 3 (17.7) 
 Hypertension, no. (%) 52 (68.4) 13 (76.5) 
 Diabetes, no. (%) 21 (27.6) 8 (47.1) 
 Stroke, no. (%) 12 (15.8) 2 (11.8) 
 Tobacco use, no. (%) 36 (47.4) 12 (70.6) 
Appointment attendance < 75%, no. (%) 46 (60.5) 









SAMe-TT2R2 ≤ 2, no. (%) 19 (25.0) Mean score 
(Range) 
4.8 
(3-7) SAMe-TT2R2 > 2, no. (%) 57 (75.0) 
Note. Table 1 illustrates baseline characteristics of the population managed. Of note, all high-risk warfarin patients had an appointment attendance  
< 75%, TTR < 60%, and SAMe-TT2R2 > 2; therefore Table 1 displays the mean and range for these data points for high-risk warfarin patients 
 
Figure 3. Primary endpoint
Table 2. Secondary endpoints
 
 
Event High-risk Warfarin Patients 
Major bleeding event, no. (%) 0 (0) 
Side effects, no. (%) 2 (20) 
Thrombotic events, no. (%) 0 (0) 
Physician acceptance, no. (%) 17 (100) 
Overall Clinic TTR, (%) Pre-implementation, 60.9 Post-implementation, 81.1 
Mean PDC, (%) Before transition to DOAC, 87.5 After transition to DOAC, 94 
 
A total of 10 high-risk patients were transitioned to a DOAC
(see Figure 3). The percentage of high-risk warfarin patients
was reduced by 13.2% (from 22.4% to 9.2%) after program
implementation. No major bleeding events or thrombotic
events have been reported since the publication of this article.
One patient reported headaches after initiation of rivaroxa-
ban, a treatment-emergent adverse event reported in 4.56%
of the treatment arm in the ROCKET-AF study.[13] The side
effect resolved in this patient after weeks of continuing ri-
varoxaban, but other clinical factors including hypoglycemia
which the patient also experienced around the same time of
rivaroxaban initiation may have contributed. Another pa-
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tient reported nausea but this patient also experienced nausea
while on warfarin. This patient was switched to a different
DOAC and further follow-up will be provided.
All warfarin-to-DOAC pharmacist recommendations to PCPs
were accepted (see Table 2). Medication adherence evalua-
tion using PDC was 60% prior to the study. After the study,
the PDC was 94%, indicating an improvement in patients
transitioned to DOAC. The overall TTR for the clinic also
improved from 60.9% to 81.1%. Most patients reported sat-
isfaction with the switch from warfarin to DOAC, with a
median score of 5, indicating very satisfied, for most of the
survey items (see Table 3).
Table 3. Satisfaction survey of high-risk warfarin patients switched from warfarin to DOAC therapy
 
 
 Very dissatisfied 
(Score = 1) 
No., (%) 
Dissatisfied 
(Score = 2) 
No., (%) 
Neutral 
(Score = 3) 
No., (%) 
Satisfied 
(Score = 4) 
No., (%) 
Very Satisfied 




Switch from warfarin 0 0 1 (10) 3 (30) 6 (60) 5 
Lack of laboratory monitoring 0 0 1 (10) 3 (30) 6 (60) 5 
Lower bleed risk 0 0 3 (30) 1 (10) 6 (60) 5 
Less food interactions 0 0 2 (20) 2 (20) 6 (60) 5 
Less drug interactions 0 0 3 (30) 3 (30) 4 (40) 4 
Efficacy 0 0 3 (30) 2 (20) 5 (50) 4.5 
Dosing 0 0 2 (20) 1 (10) 7 (70) 5 
Cost 0 0 1 (10) 1 (10) 8 (80) 5 
Education provided by clinic team 0 0 0 3 (30) 7 (70) 5 
Follow-up by clinic team 0 0 0 2 (20) 8 (80) 5 
 
4. DISCUSSION
A pharmacy resident successfully piloted a process to con-
vert high-risk warfarin patients to DOACs with no reports of
significant adverse drug events. We used an interprofessional
population management strategy to risk stratify patients and
implement changes. Medical staff was overall receptive to
pharmacist recommendations as illustrated by the acceptance
rate. High-risk warfarin patients who were not switched to
DOACs were due to patient refusal. A common barrier was
patient preference to remain on warfarin, even after educa-
tion on risks and benefits of warfarin compared to DOAC
therapy were provided. This is perhaps due to the prospec-
tive laboratory monitoring with warfarin providing closure
regarding therapeutic safety and efficacy, in addition to more
interaction with the clinical team.[14, 15]
Cost was another common but not a complete barrier to tran-
sitioning to a DOAC. In some situations, DOAC copays were
less than the combined cost of warfarin copays, clinic ap-
pointment copays and transportation. In other instances, free
samples or copay cards were provided to help offset cost.
Patients without insurance were enrolled in pharmaceutical
manufacturer patient assistance programs (PAPs). The cost
strategies utilized in this pilot study have been adopted in
our clinic for any patient started on a DOAC. Physicians
and clinic staff now re-direct patients with cost barriers to
multidisciplinary members including a financial counselor,
social worker, or clinical pharmacist for DOAC cost support.
Nurses facilitate prior authorizations, but, if unsuccessful,
will re-direct patients through this process as well. A fu-
ture pilot study will be implemented to provide continuous
DOAC monitoring, including re-assessments of financial and
insurance status to help ensure patients can be maintained on
DOAC therapy.
The three high-risk criteria were selected in order to identify
patients most likely to benefit from transitioning to DOACs.
Relying solely on TTR may provide an inaccurate assess-
ment of INR control. For instance, new-start warfarin pa-
tients are more likely to have labile INRs, leading to a low
TTR initially, not necessarily indicating poor candidacy for
long-term therapy with warfarin. Also, if an INR is out of
range and the time between measurements is long (e.g. due
to high no-show rate), the TTR will be falsely low. Other sce-
narios may include medication, dietary, or acute illness.[10]
We added the criteria of appointment adherence and SAMe-
TT2R2 score to account for potential pitfalls of the TTR. The
change in percentage of high-risk warfarin patients may have
been greater if only 2 rather than 3 criteria were utilized. We
plan to expand our pilot to more patients who may be better
suited for DOAC therapy by changing the criteria utilized
(e.g. TTR plus SAMe-TT2R2, TTR plus appointment adher-
ence, or appointment adherence plus SAMe-TT2R2) and we
encourage exploration of other approaches individualized to
each practice setting.
Poor INR history was defined as TTR < 60% considering the
average TTR reported in clinical trials comparing warfarin
to DOACs as well as data reporting capabilities specific to
the Dose Response R© system. Facilities may lack software
to calculate TTR which may limit the application of this
approach at other institutions. Other methods of calculating
TTR that can be used include (1) the proportion of patients
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with a therapeutic INR at a specific point in time or (2) num-
ber of therapeutic INRs over total number visits over a period
of time, but these methods have been found to overestimate
TTR. If TTR is not available, other criteria may be used such
as clinic appointment adherence and/or the SAMe-TT2R2
score.
The appointment adherence cut-point of 75% was adopted
from a study of a different population demographic due to a
lack of literature on the concept.[16] The SAMe-TT2R2 scor-
ing tool was utilized as the last high-risk criteria to strengthen
the ability to identify patients with poor anticoagulation con-
trol on warfarin. The SAMe-TT2R2 was internally validated
using data from the AFFIRM trial for patients with AF.[11]
Other external validations with real world patient cohorts
have assessed the predictive value of this scoring tool.[17] It
has been associated with outcomes data, making it a poten-
tial first step in the patient management pathway to help in
identifying patients at high-risk of poor anticoagulation con-
trol. Our study population included indications for VTE and
NVAF. There are currently no validated warfarin risk scoring
tools for VTE patients. Therefore, we utilized the SAMe-
TT2R2 score in our patient population because we consider
clinical risk factors to be similar for both indications.
Initial appointments to transition to a DOAC required 30-
45 minutes compared to standard 15-minute warfarin clinic
follow up appointments. The extended appointment times
were needed for patient education, laboratory monitoring,
and addressing financial barriers. However, DOAC follow
up appointments via face-to-face or telephonic were easily
manageable.
Adherence is an ongoing barrier to anticoagulation therapy.
As a standard of care, warfarin patients in our anticoagu-
lation clinic are provided adherence education with further
adherence support such as pill boxes and calendars depend-
ing on patient barriers. Patients may continue to have poor
adherence despite these interventions, potentially due to so-
cioeconomic challenges. Of our entire clinic population,
around 20% are uninsured and receive charity care. Fur-
thermore, it is estimated that 50% of our clinic population
is indigent, regardless of insurance status. Therefore, the
monthly cost of warfarin, although priced at around $4, is
likely to be unaffordable for many patients, especially those
with numerous medications and in addition to copay costs
for INR monitoring. Patients may also have transportation
challenges understanding the necessity of treatment or may
be apprehensive about adverse effects. Challenges following
dosing instructions which can be complex with warfarin, re-
membering to take medications, and maintaining a consistent
dietary intake may also be present in our population. Using
the 3 criteria in this pilot study provided justification that the
risk of clinical events outweighs the benefits of continuing
or re-trying warfarin in the patients selected.
We utilized PDC, a method endorsed by the Pharmacy Qual-
ity Alliance to evaluate adherence by determining the pro-
portion of days in the measurement period covered by pre-
scription claims. A PDC threshold of 80% indicates the
medication has a reasonable likelihood of achieving most of
the potential clinical benefit.[18] The high adherence rate for
DOAC patients seen in this pilot study may be due to the
repeated patient telephone outreach in which education and
compliance was strongly emphasized in addition to reduced
cost burden for many patients (e.g. free access to DOACs
through PAPs, avoidance of office visit copays for warfarin
INR monitoring). Other factors influencing patient adherence
to DOAC therapy may be related to increased satisfaction
over warfarin (see Table 3).[14]
After implementation of the warfarin-to-DOAC pilot, there
was an increase in overall clinic TTR comparing pre- to post-
analysis. Thus, although there is currently a lack of research
on this concept, switching high-risk warfarin patients to other,
potentially more suitable therapies, is a strategy for antico-
agulation clinic improvement where TTR serves as a quality
indicator. The initial lower TTR, and also appointment adher-
ence, is potentially due to the aforementioned socioeconomic
challenges in our patient population. These findings further
support the importance of having a systematic approach for
optimizing anticoagulation population management in the
clinic setting.
5. CONCLUSIONS
A pilot process was successful in reducing the percentage of
high-risk warfarin patients by switching to DOAC therapy.
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